TY - JOUR
T1 - Interferon γ regulates accumulation of the proteasome activator PA28 and immunoproteasomes at nuclear PML bodies
AU - Fabunmi, Rosalind P.
AU - Christian Wigley, W.
AU - Thomas, Philip J.
AU - DeMartino, George N.
PY - 2001
Y1 - 2001
N2 - PA28 is an interferon γ (IFNγ) inducible proteasome activator required for presentation of certain major histocompatibility (MHC) class I antigens. Under basal conditions in HeLa and Hep2 cells, a portion of nuclear PA28 is concentrated at promyelocytic leukemia oncoprotein (PML)-containing bodies also commonly known as PODs or ND10. IFNγ treatment greatly increased the number and size of the PA28- and PML-containing bodies, and the effect was further enhanced in serum-deprived cells. PML bodies are disrupted in response to certain viral infections and in diseases such as acute promyelocytic leukemia (APL). Like PML, PA28 was delocalized from PML bodies by expression of the cytomegalovirus protein, IE1, and in NB4 cells, an APL model line. Moreover, retinoic acid treatment, which causes remission of APL in patients and reformation of PML-containing bodies in NB4 cells, relocalized PA28 to this site. In contrast, the proteasome, the functional target of PA28, was not detected at PML bodies under basal conditions in HeLa and Hep2 cells, but IFNγ promoted accumulation of 'immunoproteasomes' at this site. These results establish PA28 as a novel component of nuclear PML bodies, and suggest that PA28 may assemble or activate immunoproteasomes at this site as part of its role in proteasome-dependent MHC class I antigen presentation.
AB - PA28 is an interferon γ (IFNγ) inducible proteasome activator required for presentation of certain major histocompatibility (MHC) class I antigens. Under basal conditions in HeLa and Hep2 cells, a portion of nuclear PA28 is concentrated at promyelocytic leukemia oncoprotein (PML)-containing bodies also commonly known as PODs or ND10. IFNγ treatment greatly increased the number and size of the PA28- and PML-containing bodies, and the effect was further enhanced in serum-deprived cells. PML bodies are disrupted in response to certain viral infections and in diseases such as acute promyelocytic leukemia (APL). Like PML, PA28 was delocalized from PML bodies by expression of the cytomegalovirus protein, IE1, and in NB4 cells, an APL model line. Moreover, retinoic acid treatment, which causes remission of APL in patients and reformation of PML-containing bodies in NB4 cells, relocalized PA28 to this site. In contrast, the proteasome, the functional target of PA28, was not detected at PML bodies under basal conditions in HeLa and Hep2 cells, but IFNγ promoted accumulation of 'immunoproteasomes' at this site. These results establish PA28 as a novel component of nuclear PML bodies, and suggest that PA28 may assemble or activate immunoproteasomes at this site as part of its role in proteasome-dependent MHC class I antigen presentation.
KW - IFN gamma
KW - LMP
KW - PA28
KW - PML
KW - Proteasome
UR - http://www.scopus.com/inward/record.url?scp=0035147230&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0035147230&partnerID=8YFLogxK
M3 - Article
C2 - 11112687
AN - SCOPUS:0035147230
SN - 0021-9533
VL - 114
SP - 29
EP - 36
JO - The Quarterly journal of microscopical science
JF - The Quarterly journal of microscopical science
IS - 1
ER -